Table 2 Adverse events of any grade reported in 10% or more patients during study treatment, regardless of causality
| Â | Number (%) of patients* | |||
|---|---|---|---|---|
| Â | Ganetespib | Ganetespib | Ganetespib | All |
7-114Â mg/m2 | 150-216Â mg/m2 | 259Â mg/m2 | patients | |
n = 25 (%) | n = 22 (%) | n = 6 (%) | n = 53 (%) | |
Any event | 25 (100) | 22 (100) | 6 (100) | 53 (100) |
Diarrhea | 20 (60) | 21 (95.5) | 6 (100) | 47 (88.7) |
Fatigue | 12 (48) | 13 (59.1) | 5 (83.3) | 30 (56.6) |
Abdominal pain | 9 (36) | 10 (45.5) | 1 (16.7) | 20 (37.7) |
Nausea | 7 (28) | 7 (31.8) | 4 (66.7) | 18 (34) |
Anemia | 11 (44) | 5 (22.7) | 0 | 16 (30.2) |
Decreased appetite | 2 (8) | 8 (36.4) | 1 (16.7) | 11 (20.8) |
ALT elevated | 5 (20) | 5 (22.7) | 0 | 10 (18.9) |
Insomnia | 2 (8) | 6 (27.3) | 2 (33.3) | 10 (18.9) |
Vomiting | 4 (16) | 3 (13.6) | 3 (50) | 10 (18.9) |
AST elevated | 5 (20) | 4 (18.2) | 0 | 9 (17) |
Constipation | 5 (20) | 3 (13.6) | 1 (16.7) | 9 (17) |
Dyspnea | 4 (16) | 4 (18.2) | 1 (16.7) | 9 (17) |
Headache | 2 (8) | 6 (27.3) | 1 (16.7) | 9 (17) |
Peripheral edema | 3 (12) | 5 (22.7) | 1 (16.7) | 9 (17) |
Asthenia | 2 (8) | 4 (18.2) | 2 (33.3) | 8 (15.1) |
Back pain | 4 (16) | 2 (9.1) | 2 (33.3) | 8 (15.1) |
Urinary tract infection | 2 (8) | 3 (13.6) | 3 (50) | 8 (15.1) |
Dehydration | 1 (4) | 3 (13.6) | 3 (50) | 7 (13.2) |
Hypokalemia | 2 (8) | 4 (18.2) | 1 (16.7) | 7 (13.2) |
Hypophosphatemia | 5 (20) | 2 (9.1) | 0 | 7 (13.2) |
Weight decreased | 1 (4) | 5 (22.7) | 1 (16.7) | 7 (13.2) |
Abdominal distension | 3 (12) | 3 (13.6) | 0 | 6 (11.3) |
ALT elevated | 3 (12) | 3 (13.6) | 0 | 6 (11.3) |
Dizziness | 1 (4) | 3 (13.6) | 2 (33.3) | 6 (11.3) |
Dry mouth | 2 (8) | 3 (13.6) | 1 (16.7) | 6 (11.3) |
Musculoskeletal chest pain | 2 (8) | 4 (18.2) | 0 | 6 (11.3) |
Extremity pain | 4 (16) | 1 (4.5) | 1 (16.7) | 6 (11.3) |
Rash | 4 (16) | 1 (4.5) | 1 (16.7) | 6 (11.3) |